July 2022: Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) received accelerated approval from the Food and Drug Administration for the treatment of adult and paediatric patients ol...
novartis
June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or refract...
novartis
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patie...
novartis
March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment's remarkable effect on tumours comes at the expense of subs...
novartis
Immunotherapy in treatment of cancerCancer CAR-NK therapy has an effective rate of 73%, and is being recruited in domestic clinical trials.Immunotherapy has revolutionized the way cancer is treated. ...
novartis